Daniel Pluznik, MD
Ophthalmology · Washington, DCNPI 1699871194
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.
Across 167 payments — averaging $36.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- NEW World Medical,inc.$1K
- Bausch & Lomb Americas Inc.$609
- Alcon$410
- Biotissue Holdings Inc.$370
- Tarsus Pharmaceuticals, Inc.$363
- plus $2K from 23 others
Across 10 payments — averaging $5600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$56K
What the payments were for
- Food & beverage$6,131100%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $1,134 |
| NEW World Medical,inc. | 6 | $1,017 |
| Bausch & Lomb Americas Inc. | 9 | $609 |
| Alcon | 15 | $410 |
| Biotissue Holdings Inc. | 7 | $370 |
| Tarsus Pharmaceuticals, Inc. | 9 | $363 |
| Heru, Inc. | 1 | $340 |
| Novartis | 22 | $310 |
| Sun Pharmaceutical Industries Inc. | 9 | $286 |
| Kala Pharmaceuticals, Inc. | 9 | $193 |
| Shire North American Group Inc | 2 | $140 |
| Aerie Pharmaceuticals, Inc. | 2 | $138 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $137 |
| Apellis Pharmaceuticals, Inc. | 1 | $119 |
| Astellas Pharma US Inc | 1 | $111 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $62 |
| Dompe US, Inc. | 2 | $56 |
| Glaukos Corporation | 1 | $55 |
| Rxsight Inc | 2 | $54 |
| Harrow Eye, LLC | 2 | $38 |
| Sight Sciences, Inc. | 2 | $38 |
| Oyster Point Pharma, Inc. | 2 | $26 |
| Carl Zeiss Meditec, Inc. | 1 | $25 |
| Tearlab Corp | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Thea Pharma Inc. | 1 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Omeros Corporation | 1 | $15 |
| Johnson & Johnson Vision Care, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$770
- Kahook Dual Blade$770
- Streamline Surgical System$531
- XIIDRA$405
- MIEBO$399
- Heru HMD$340
- Prokera$148
- AmnioGraft$148
- IC-8 Apthera IOL$123
- enVista MX60 IOL$123
- LUMIGAN$121
- VUITY$120
- XDEMVY$120
- Syfovre$119
- Rhopressa$116
- Rocklatan$116
- CEQUA$116
- Izervay$111
How this compares
$6,150 in reported general payments places this provider in the 85th percentile of 74 ophthalmology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 13 | $18,500 |
| XiidraLifitegrast | 17 | $18,062 |
| LumiganBimatoprost | 31 | $16,411 |
| Alphagan PBrimonidine Tartrate | 27 | $11,539 |
| MieboPerfluorohexyloctane/Pf | 11 | $8,351 |
| Prednisolone Acetate | 71 | $1,964 |
| Latanoprost | 104 | $1,300 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 35 | $589 |
| Timolol Maleate | 43 | $355 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 12 | $141 |
| ErythromycinErythromycin Base | 11 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $1,134 | $46,45071 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $609 | $26,41328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 74 ophthalmology providers in District of Columbia.
Other ophthalmology in Washington
- Wiley ChambersWashington$618K
- Keesha Williams ElliottWashington$167K
- Samuel StopakWashington$33K
- Jonca BullWashington$30K
- Leslie JonesWashington$22K
- Alexander HacopianWashington$13K
- Mehdi Tavakoli DastjerdiWashington$12K
- Andrew HammerWashington$11K
- Thandeka MyeniWashington$10K
- Dipak PanigrahiWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.